Standard Treatments for Acute Yeast Infections
At a Glance
Acute vulvovaginal candidiasis is usually treated with a vaginal azole or oral fluconazole, but severe infections may need longer or repeated treatment. During pregnancy, a 7-day topical vaginal cream is generally recommended; oral fluconazole is generally avoided and ibrexafungerp must not be used.
When you are diagnosed with an acute (occasional) yeast infection, the goal of treatment is to clear the overgrowth of yeast and calm the resulting inflammation. Doctors generally categorize these infections as either uncomplicated or complicated, which determines the strength and length of your treatment [1][2].
Uncomplicated vs. Complicated VVC
Most yeast infections are considered uncomplicated. This means the symptoms are mild to moderate, they happen infrequently, and you are otherwise healthy [1].
An infection is considered complicated (or severe) if:
- Symptoms are intense (extreme redness, swelling, or skin fissures/cracks) [3].
- It is caused by a non-albicans species of yeast [4].
- You are pregnant [1].
- You have uncontrolled diabetes or a weakened immune system [5][6].
Standard Azole Treatments
The most common treatments belong to a class of drugs called azoles. These work by inhibiting ergosterol synthesis, which disrupts the cell membrane of the yeast [1].
- Topical Azoles (Creams and Suppositories): These are available both over-the-counter (OTC) and by prescription. They are applied directly into the vagina for 1, 3, or 7 days [1]. Common examples include miconazole and clotrimazole. Caution: Oil-based vaginal azoles can weaken latex condoms and diaphragms, reducing their effectiveness as contraception.
- Oral Fluconazole: This is a prescription pill, usually taken as a single 150-mg dose [7].
Which is better? Research shows that topical creams and the oral pill are generally equally effective at curing uncomplicated infections [1][8]. Topical treatments are more likely to cause local burning or irritation, while the oral pill may cause mild systemic side effects like headache, nausea, or abdominal pain [8]. If an OTC cream burns intensely, it might be an irritant reaction or a sign that the diagnosis is incorrect; stop using it and consult a doctor.
Treatment for Severe Acute Episodes
If your infection is classified as severe or complicated, a single dose of medication may not be enough. These regimens require clinician direction.
- Two-Dose Regimen: For severe symptoms, doctors often prescribe two doses of oral fluconazole (150 mg), taken three days apart (usually on day 1 and day 4) [9].
- Extended Topicals: Alternatively, a longer course of topical cream (7 to 14 days) may be used instead of a short 1- or 3-day course [2][10].
Ibrexafungerp: A Non-Azole Option
Ibrexafungerp is a newer, oral medication for acute VVC. It is not an azole; it belongs to a different class of drugs that kills yeast by a different mechanism [11]. It may be an option if you are allergic to azoles or if the yeast is resistant to standard treatments [11].
- Dosing: The standard dose is two 150-mg tablets taken twice in one day (total of four tablets), with the two doses spaced 12 hours apart [12][13].
- Side Effects: The most common side effects are gastrointestinal, including diarrhea, nausea, and abdominal pain [13][12].
- Drug Interactions: Ibrexafungerp can interact with other medications. Your doctor may need to adjust the dose if you are taking certain drugs that affect liver enzymes (CYP3A4 inhibitors or inducers) [13].
Critical Safety Warnings
Safety is the top priority when choosing a treatment, especially regarding pregnancy.
- Pregnancy Warning for Fluconazole: Oral fluconazole should generally be avoided during pregnancy (even low-dose single pills). Use has been associated with a small increased risk of spontaneous abortion (miscarriage) and certain birth defects, such as heart or bone malformations [1][14][15]. In addition, fluconazole has clinically important drug interactions and rare liver and QT-related heart risks.
- Pregnancy Contraindication for Ibrexafungerp: Ibrexafungerp is strictly contraindicated (must not be used) during pregnancy [13][11]. If you are of childbearing age, your doctor may require a pregnancy test before prescribing it [13].
- Standard for Pregnancy: For pregnant patients, the safest and most recommended treatment is a 7-day course of topical vaginal cream [1][16].
If you find that your symptoms return shortly after finishing an acute treatment course, you may be dealing with recurrent VVC, which requires a different, long-term management strategy.
Common questions in this guide
What is the usual treatment for an uncomplicated vaginal yeast infection?
Are vaginal yeast infection creams better than an oral pill?
What is recommended for a yeast infection during pregnancy?
How is a severe or complicated yeast infection treated?
What is ibrexafungerp, and when might it be used for VVC?
What should I do if an over-the-counter yeast infection cream burns intensely?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Treatment options
How would a topical cream and an oral pill compare for my infection?
Side effects
What side effects might I notice from a topical cream compared with an oral pill?
Other treatment options
Could an oral non-azole medicine such as ibrexafungerp be an option for me?
Get notified when new evidence is published on vulvovaginal candidiasis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines.
Nyirjesy P, Brookhart C, Lazenby G, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022; (74(Suppl_2)):S162-S168 doi:10.1093/cid/ciab1057.
PMID: 35416967 - 2
Treatment of vulvovaginal candidiasis: a review of the literature.
Dovnik A, Golle A, Novak D, et al.
Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2015; (24(1)):5-7 doi:10.15570/actaapa.2015.2.
PMID: 25770305 - 3
A Comprehensive Overview of Candida albicans as the Leading Pathogen in Vulvovaginal Candidiasis.
Srb N, Talapko J, Meštrović T, et al.
Journal of fungi (Basel, Switzerland) 2025; (11(9)) doi:10.3390/jof11090632.
PMID: 41003178 - 4
Non-albicans Candida and rare yeasts in vulvovaginal candidiasis: pathogen attribution, antifungal resistance, persistence, and species-informed management.
Yan Z, Cui Y, Li Y, et al.
Frontiers in microbiology 2026; (17()):1944046 doi:10.3389/fmicb.2026.1944046.
PMID: 42780976 - 5
Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors.
Gonçalves B, Ferreira C, Alves CT, et al.
Critical reviews in microbiology 2016; (42(6)):905-27 doi:10.3109/1040841X.2015.1091805.
PMID: 26690853 - 6
Vaginitis: Diagnosis and Treatment.
Paladine HL, Desai UA
American family physician 2018; (97(5)):321-329.
PMID: 29671516 - 7
Clotrimazole for Vulvovaginal Candidosis: More Than 45 Years of Clinical Experience.
Mendling W, Atef El Shazly M, Zhang L
Pharmaceuticals (Basel, Switzerland) 2020; (13(10)) doi:10.3390/ph13100274.
PMID: 32992877 - 8
Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush).
Denison HJ, Worswick J, Bond CM, et al.
The Cochrane database of systematic reviews 2020; (8()):CD002845 doi:10.1002/14651858.CD002845.pub3.
PMID: 32845024 - 9
Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial.
Wang X, Chen L, Ruan H, et al.
Antimicrobial agents and chemotherapy 2024; (68(1)):e0077823 doi:10.1128/aac.00778-23.
PMID: 38095426 - 10
Miconazole nitrate vaginal suppository 1,200 mg versus oral fluconazole 150 mg in treating severe vulvovaginal candidiasis.
Fan S, Liu X, Liang Y
Gynecologic and obstetric investigation 2015; (80(2)):113-8 doi:10.1159/000371759.
PMID: 25720546 - 11
Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy.
Phillips NA, Rocktashel M, Merjanian L
Drug design, development and therapy 2023; (17()):363-367 doi:10.2147/DDDT.S339349.
PMID: 36785761 - 12
Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).
Sobel R, Nyirjesy P, Ghannoum MA, et al.
BJOG : an international journal of obstetrics and gynaecology 2022; (129(3)):412-420 doi:10.1111/1471-0528.16972.
PMID: 34676663 - 13
Ibrexafungerp: A new triterpenoid antifungal.
Sucher AJ, Thai A, Tran C, et al.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2022; (79(24)):2208-2221 doi:10.1093/ajhp/zxac256.
PMID: 36083109 - 14
Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth.
Mølgaard-Nielsen D, Svanström H, Melbye M, et al.
JAMA 2016; (315(1)):58-67 doi:10.1001/jama.2015.17844.
PMID: 26746458 - 15
Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study.
Zhu Y, Bateman BT, Gray KJ, et al.
BMJ (Clinical research ed.) 2020; (369()):m1494 doi:10.1136/bmj.m1494.
PMID: 32434758 - 16
Vulvovaginal candidiasis in pregnancy.
Aguin TJ, Sobel JD
Current infectious disease reports 2015; (17(6)):462 doi:10.1007/s11908-015-0462-0.
PMID: 25916994
This page explains treatment options and safety considerations for acute vulvovaginal candidiasis for informational purposes only and does not constitute medical advice. Ask a clinician before using oral medicines, especially during pregnancy or with other medications.